Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2023 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's own repeatable business is escalating. We need to look for management's own words that compare current deals/contracts/projects to past ones, showing that each new instance is individually larger, broader, or longer. Scanning the transcript: The call discusses Baozun's three business lines: E-Commerce, Brand Management, and International. They mention adding new brands, expanding into new channels, and the Hunter deal. But does management say that the deals they are landing now are individually larger than before? They talk about adding 41 new brands, but that's more volume. They talk about the Hunter deal as a strategic partnership with ABG, but they don't compare its size to previous deals. They mention that BBM is adding Hunter to its portfolio, but they don't say that Hunter is a larger deal than Gap or that the scale of deals is increasing. They also mention that they are forming a joint venture with ABG to co-own IP, but that's a new type of deal, not necessarily larger. The question specifically asks about "successive engagements of the same kind" coming in at progressively larger size. For example, if they were signing licensing deals, are the new ones bigger? They mention that Hunter is a good addition, but they don't compare its size to Gap. They also say that they anticipate needing only a few additional members to run Hunter, implying it's small. So no indication of escalation in unit size. They also talk about the E-Commerce business transitioning to a second growth curve, but that's about strategy, not about deal size. They mention that they have a stronger pipeline in the second half, but that's about number of deals, not size. Thus, management does not convey that the individual size of what they land has grown versus their own past. They talk about more brands, more channels, but not larger deals per se. The Hunter deal is a new partnership, but they don't frame it as part of an upward drift in deal size. They also mention that they are being selective, but that doesn't imply larger. Therefore, the answer is NO. We need to answer only YES or NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.